Zi-Feng Yang (Zifeng Yang)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 13

Top Topics

Respiratory Syndrome Coronavirus

Saccharomyces Cerevisiae

Anti Inflammatory

Top Venues

Nature microbiology

Evidence-based complementary and alternative medicine : eCAM

BMC public health

This page only lists publications with an associated author ORCID identifier.

Publications

Xiaoxin Chen, Xiaodong Huang, Qinhai Ma, Petr Kuzmič, Biao Zhou, Sai Zhang, Jizheng Chen, Jinxin Xu, Bin Liu, Haiming Jiang, Wenjie Zhang, Chunguang Yang, Shiguan Wu, Jianzhou Huang, Haijun Li, Chaofeng Long, Xin Zhao, Hongrui Xu, Yanan Sheng, Yaoting Guo, Chuanying Niu, Lu Xue, Yong Xu, Jin-Song Liu, Tian-Yu Zhang, James Spencer, Zhenzhen Zhu, Wenbing Deng, Xinwen Chen, Shu-Hui Chen, Nan-Shan Zhong, Xiaoli Xiong, Zi-Feng Yang
Preclinical evaluation of the SARS-CoV-2 M pro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nature microbiology 9 (4) (2024)
Yang Wang, Qinhai Ma, Man Li, Qianyi Mai, Lin Ma, Hong Zhang, Huiling Zhong, Kailin Mai, Nan Cheng, Pei Feng, Peikun Guan, Shengzhen Wu, Lu Zhang, Jun Dai, Biliang Zhang, Weiqi Pan, Zi-Feng Yang
A decavalent composite mRNA vaccine against both influenza and COVID-19. mBio (2024)
Xiaoxin Chen, Xiaodong Huang, Qinhai Ma, Petr Kuzmič, Biao Zhou, Sai Zhang, Jizheng Chen, Jinxin Xu, Bin Liu, Haiming Jiang, Wenjie Zhang, Chunguang Yang, Shiguan Wu, Jianzhou Huang, Haijun Li, Chaofeng Long, Xin Zhao, Hongrui Xu, Yanan Sheng, Yaoting Guo, Chuanying Niu, Lu Xue, Yong Xu, Jin-Song Liu, Tian-Yu Zhang, James Spencer, Zhenzhen Zhu, Wenbing Deng, Xinwen Chen, Shu-Hui Chen, Nan-Shan Zhong, Xiaoli Xiong, Zi-Feng Yang
Preclinical evaluation of the SARS-CoV-2 M pro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nature microbiology 9 (4) (2024)
Xiaoxin Chen, Xiaodong Huang, Qinhai Ma, Petr Kuzmič, Biao Zhou, Sai Zhang, Jizheng Chen, Jinxin Xu, Bin Liu, Haiming Jiang, Wenjie Zhang, Chunguang Yang, Shiguan Wu, Jianzhou Huang, Haijun Li, Chaofeng Long, Xin Zhao, Hongrui Xu, Yanan Sheng, Yaoting Guo, Chuanying Niu, Lu Xue, Yong Xu, Jin-Song Liu, Tian-Yu Zhang, James Spencer, Zhenzhen Zhu, Wenbing Deng, Xinwen Chen, Shu-Hui Chen, Nan-Shan Zhong, Xiaoli Xiong, Zi-Feng Yang
Preclinical evaluation of the SARS-CoV-2 M pro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nature microbiology 9 (4) (2024)
Xiaoxin Chen, Xiaodong Huang, Qinhai Ma, Petr Kuzmič, Biao Zhou, Sai Zhang, Jizheng Chen, Jinxin Xu, Bin Liu, Haiming Jiang, Wenjie Zhang, Chunguang Yang, Shiguan Wu, Jianzhou Huang, Haijun Li, Chaofeng Long, Xin Zhao, Hongrui Xu, Yanan Sheng, Yaoting Guo, Chuanying Niu, Lu Xue, Yong Xu, Jin-Song Liu, Tian-Yu Zhang, James Spencer, Zhenzhen Zhu, Wenbing Deng, Xinwen Chen, Shu-Hui Chen, Nan-Shan Zhong, Xiaoli Xiong, Zi-Feng Yang
Preclinical evaluation of the SARS-CoV-2 M pro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nature microbiology 9 (4) (2024)
Xiaoxin Chen, Xiaodong Huang, Qinhai Ma, Petr Kuzmič, Biao Zhou, Sai Zhang, Jizheng Chen, Jinxin Xu, Bin Liu, Haiming Jiang, Wenjie Zhang, Chunguang Yang, Shiguan Wu, Jianzhou Huang, Haijun Li, Chaofeng Long, Xin Zhao, Hongrui Xu, Yanan Sheng, Yaoting Guo, Chuanying Niu, Lu Xue, Yong Xu, Jin-Song Liu, Tian-Yu Zhang, James Spencer, Zhenzhen Zhu, Wenbing Deng, Xinwen Chen, Shu-Hui Chen, Nan-Shan Zhong, Xiaoli Xiong, Zi-Feng Yang
Preclinical evaluation of the SARS-CoV-2 M pro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nature microbiology 9 (4) (2024)
Xiaoxin Chen, Xiaodong Huang, Qinhai Ma, Petr Kuzmič, Biao Zhou, Sai Zhang, Jizheng Chen, Jinxin Xu, Bin Liu, Haiming Jiang, Wenjie Zhang, Chunguang Yang, Shiguan Wu, Jianzhou Huang, Haijun Li, Chaofeng Long, Xin Zhao, Hongrui Xu, Yanan Sheng, Yaoting Guo, Chuanying Niu, Lu Xue, Yong Xu, Jin-Song Liu, Tian-Yu Zhang, James Spencer, Zhenzhen Zhu, Wenbing Deng, Xinwen Chen, Shu-Hui Chen, Nan-Shan Zhong, Xiaoli Xiong, Zi-Feng Yang
Preclinical evaluation of the SARS-CoV-2 M pro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nature microbiology (2024)
Hongxia Zhou, Peifang Xie, Minshan Qiu, Shuwei Dong, Xue-Shan Xia, Zi-Feng Yang, Yaoqin Yuan, Lihan Shen
Arbidol increases the survival rate by mitigating inflammation in suckling mice infected with human coronavirus OC43 virus. Journal of medical virology 95 (9) (2023)
Yong Liu, Wenxiang Jin, Wenda Guan, Zhiqi Zeng, Zi-Feng Yang
The genetic characterization of hemagglutinin (HA), neuraminidase (NA) and polymerase acidic (PA) genes of H3N2 influenza viruses circulated in Guangdong Province of China during 2019-2020. Virus genes 58 (5) (2022)
Jin Zhao, Yanbing Hao, Xuanzi Xia, Runfeng Li, Xiaodong Huang, Zi-Feng Yang, Xinhua Wang
Chaiqin Qingning Capsule Inhibits Influenza Virus Infection and Inflammation In Vitro and In Vivo. Evidence-based complementary and alternative medicine : eCAM 2021 (2021)
Eunice Yuen Chi Shiu, Wenbo Huang, Dan Ye, Yanmin Xie, Jinhan Mo, Yuguo Li, Benjamin John Cowling, Zi-Feng Yang, Nancy Hiu Lan Leung
Frequent recovery of influenza A but not influenza B virus RNA in aerosols in pediatric patient rooms. Indoor air 30 (5) (2020)
Chunguang Yang, Yutao Wang, Jiayang He, Wen Yan, Haiming Jiang, Qiaolian Chen, Li Li, Zi-Feng Yang
Lianhua-Qingwen Displays Antiviral and Anti-Inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model. Evidence-based complementary and alternative medicine : eCAM 2020 (2020)
Qiao-Yan Chen, Li Li, Li Zhang, Jin-Han Mo, Zi-Feng Yang, Xiao-Lin Wei, Yun-Ying Li, Ji-Yan Xia, Xiao-Bing Bai, Pei-Fang Xie
Efficacy of indoor air purification in treating Artemisia (mugwort) pollen allergic rhinitis: study protocol for a randomised controlled trial. BMC public health 18 (1) (2018)